Clinical Trials Browser

Withdrawn × tislelizumab × Other solid neoplasm × Clear all

NCT05644626 2023-11-29

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Phase 1 Withdrawn

Other solid neoplasm

Solid Tumors

NCT05582031 2023-06-07

REFIT-MSS

Phase 2 Withdrawn

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Anus Neoplasms, Sarcoma, Colorectal Neoplasms, Small Cell Lung Carcinoma